It was developed in the 1990s by researchers at Monash University in Melbourne, Australia, with one goal: isolate the fat-burning portion of growth hormone and deliver those effects without the risks that come with full hGH administration
Does Research Use Only settle UK legality
Discussion The results of this study show that ARA 290 (4 mg SC) self-administered for 28 d by subjects with type 2 diabetes is not associated with significant ARA 290-related adverse events
Key benefits Why people compare it 1 70% increase in collagen thickness in double-blind clinical trials at 3% concentration 2 Visible reduction in fine lines and improved skin density within 12 weeks 3 40% improvement in skin elasticity with enhanced firmness and hydration 4 No irritation, purging, or photosensitivity - superior tolerability to retinoids 5 Stimulates collagen I, III, and V synthesis plus decorin and glycosaminoglycans 6 Modulates over 4,000 genes including anti-inflammatory and antioxidant pathways 7 Phospholipid delivery system for enhanced dermal penetration and stability 8 Accelerates wound healing and reduces scar tissue formation in research models Deep research About GHK-Cu Topical Serum GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide with the amino acid sequence Gly-His-Lys bound to a Cu2+ ion
A 2025 review by Jozwiak and colleagues surveys the peptides multifunctionality and possible medical applications (PMC11859134), and is a useful map of what has and has not been established
While some discrepancies remain, most notably opposing findings on the size of IPSC reduction after Aldh1a1 knockout (Kim et al., 2015
